Canaccord Genuity Group Cuts Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target to $150.00

Regeneron Pharmaceuticals (NASDAQ:REGN) had its target price cut by Canaccord Genuity Group from $170.00 to $150.00 in a report released on Thursday morning, MarketBeat reports. They currently have a hold rating on the biopharmaceutical company’s stock.

Several other research analysts have also recently issued reports on the stock. Bank of America cut their target price on shares of Regeneron Pharmaceuticals from $575.00 to $547.00 and set an “underperform” rating on the stock in a report on Thursday. Bernstein Bank lowered their price objective on shares of Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a research note on Tuesday, February 4th. UBS Group cut Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and cut their target price for the stock from $1,130.00 to $738.00 in a research note on Thursday, January 16th. BMO Capital Markets lowered their price target on Regeneron Pharmaceuticals from $950.00 to $903.00 and set an “overweight” rating for the company in a research report on Tuesday, February 4th. Finally, TD Cowen reduced their price objective on shares of Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a “buy” rating on the stock in a research report on Tuesday, February 4th. One analyst has rated the stock with a sell rating, six have issued a hold rating, eighteen have assigned a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $963.56.

Regeneron Pharmaceuticals Stock Performance

Regeneron Pharmaceuticals stock opened at $563.16 on Thursday. The firm has a fifty day simple moving average of $645.94 and a two-hundred day simple moving average of $738.44. The company has a quick ratio of 3.95, a current ratio of 4.73 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals has a twelve month low of $525.99 and a twelve month high of $1,211.20. The company has a market capitalization of $61.57 billion, a PE ratio of 14.71, a P/E/G ratio of 2.34 and a beta of 0.44.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, beating analysts’ consensus estimates of $11.21 by $0.86. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The company had revenue of $3.79 billion during the quarter, compared to analyst estimates of $3.76 billion. During the same quarter in the previous year, the company posted $11.86 EPS. Regeneron Pharmaceuticals’s revenue for the quarter was up 10.3% on a year-over-year basis. Research analysts expect that Regeneron Pharmaceuticals will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th were paid a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a yield of 0.63%. The ex-dividend date of this dividend was Thursday, February 20th. Regeneron Pharmaceuticals’s payout ratio is 2.30%.

Institutional Trading of Regeneron Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Pinney & Scofield Inc. bought a new stake in Regeneron Pharmaceuticals during the fourth quarter valued at about $25,000. Rakuten Securities Inc. grew its holdings in Regeneron Pharmaceuticals by 62.5% during the 4th quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company’s stock valued at $28,000 after buying an additional 15 shares in the last quarter. OFI Invest Asset Management bought a new stake in shares of Regeneron Pharmaceuticals during the fourth quarter valued at approximately $28,000. Avalon Trust Co bought a new position in shares of Regeneron Pharmaceuticals during the fourth quarter worth $36,000. Finally, Crowley Wealth Management Inc. purchased a new position in Regeneron Pharmaceuticals during the fourth quarter valued at $36,000. 83.31% of the stock is owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.